Oncolytics completes phase I Reolysin trial enrolm Oncolytics completes phase I Reolysin trial enrolment
Oncolytics Biotech Inc (C:ONC)
Shares Issued 76,606,085
Last Close 8/15/2012 $3.05
Thursday August 16 2012 - News Release
Dr. Brad Thompson reports
ONCOLYTICS BIOTECH INC. COMPLETES PATIENT ENROLLMENT IN U.S. PHASE I CLINICAL TRIAL INVESTIGATING REOLYSIN IN COMBINATION WITH FOLFIRI IN PATIENTS WITH COLORECTAL CANCER
Oncolytics Biotech Inc. has completed patient enrolment in its U.S. phase I clinical trial using Reolysin in combination with Folfiri in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022).
The trial is a 21-patient, single arm dose escalation study designed to determine a maximum tolerated dose and dose-limiting toxicities for the combination of REOLYSIN and FOLFIRI.
Eligible patients include those with histologically confirmed cancer of the colon or rectum with Kras mutation and measurable disease. They must have progressed on or within one hundred and ninety days after the last dose of an oxaliplatin regimen in the metastatic setting, or be intolerant to oxaliplatin.
The principal investigator for the study is Dr. Sanjay Goel of the Montefiore Medical Center at the Albert Einstein College of Medicine in New York.
"We are pleased to complete enrollment in this clinical study as we learn more about using REOLYSIN for the treatment of colorectal cancer," said Dr. Brad Thompson, President and CEO of Oncolytics. "Oncolytics continues to expand its colorectal cancer program and we recently announced entry into an agreement where the NCIC Clinical Trials Group would conduct an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with FOLFOX-6 plus bevacizumab (Avastin) versus FOLFOX-6 plus bevacizumab alone."
We seek Safe Harbor.
© 2012 Canjex Publishing Ltd.